24 May 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Johnson & Johnson (J&J) revealed that it is aiming to apply for approval of 10 new drugs in the US and Europe, a polio vaccine for other parts of the world and 25 variations of its existing drugs by 2017.
Dr Joaquin Duato, co-chairman, worldwide prescription drug business, J&J, said that, "Our focus is now on enhancing our pipeline to deliver the next wave of growth."
J&J's 11 experimental drugs are now in mid or late-stage patient testing and include a potential hepatitis C treatment; a version of its Invega Sustenna schizophrenia shot; drugs for three types of cancer and new vaccines for flu and rabies.The other drugs include esketamine, which is chemically related to ketamine, an anesthetic sometimes abused at raves for the high and hallucinations it can produce.
J&J this year started mid-stage patient testing of an inhaled, low-dose version of esketamine for patients not helped by other antidepressants. The promising pain drug, fulranumab, is currently being tested in patients with osteoarthritis and in patients with pain from nerve damage caused by diabetes.
Johnson & Johnson launched 11 new products since 2009, which have raked in 17 percent of its total pharma sales last year, a rise from nine percent in 2011.